Ken Griffin Arcutis Biotherapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$8.32 - $11.0 $78,208 - $103,400	9,400 Added 11.71%	89,700 $834,000
Q2 2024 Aug 14, 2024	SELL	$7.24 - $12.53 $34,028 - $58,891	-4,700 Reduced 5.53%	80,300 $746,000
Q1 2024 May 15, 2024	BUY	$3.25 - $11.77 $244,075 - $883,927	75,100 Added 758.59%	85,000 $842,000
Q4 2023 Feb 14, 2024	SELL	$1.84 - $4.82 $2,760 - $7,230	-1,500 Reduced 13.16%	9,900 $31,000
Q3 2023 Nov 14, 2023	SELL	$5.31 - $10.98 $143,370 - $296,460	-27,000 Reduced 70.31%	11,400 $60,000
Q2 2023 Aug 14, 2023	BUY	$7.51 - $15.0 $155,457 - $310,500	20,700 Added 116.95%	38,400 $365,000
Q1 2023 May 15, 2023	BUY	$10.23 - $17.14 $51,150 - $85,700	5,000 Added 39.37%	17,700 $194,000
Q4 2022 Feb 14, 2023	BUY	$13.96 - $20.4 $177,292 - $259,079	12,700 New	12,700 $187,000

197

129M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $557M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.